Characterization of Francisella tularensis Schu S4 defined mutants as live-attenuated vaccine candidates

Araceli E. Santiago1, Barbara J. Mann2, Aiping Qin2, Aimee L. Cunningham3, Leah E. Cole4,†, Christen Grassel3, Stefanie N. Vogel4, Myron M. Levine3 and Eileen M. Barry3,**

1Departments of Pediatrics, University of Virginia Children's Hospital, University of Virginia School of Medicine, Charlottesville, VA 22908, USA, 2Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA 22908, USA, 3Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA and 4Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA

*Corresponding author: Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore Street, HSF1, Room 480, Baltimore, MD 21201, USA. Tel: 410-706-5328; Fax: 410-706-6205; E-mail: ebarry@medicine.umaryland.edu
†Present address: Sanofi Pasteur Biologics, 38 Sidney Street, Cambridge, MA, USA.

One sentence summary: Mutations in guanine biosynthesis genes, but not in four other hypothetical virulence factors in highly virulent Francisella tularensis strain Schu S4 resulted in attenuation in macrophage replication and mouse virulence.

ABSTRACT

Francisella tularensis (Ft), the etiological agent of tularemia and a Tier 1 select agent, has been previously weaponized and remains a high priority for vaccine development. Ft tularensis (type A) and Ft holarctica (type B) cause most human disease. We selected six attenuating genes from the live vaccine strain (LVS; type B), F. novicida and other intracellular bacteria: FTT0507, FTT0584, FTT0742, FTT1019c (guaA), FTT1043 (mip) and FTT1317c (guaB) and created unmarked deletion mutants of each in the highly human virulent Ft strain Schu S4 (Type A) background. FTT0507, FTT0584, FTT0742 and FTT1043 Schu S4 mutants were not attenuated for virulence in vitro or in vivo. In contrast, Schu S4 gua mutants were unable to replicate in murine macrophages and were attenuated in vivo, with an i.n. LD50 > 10^5 CFU in C57BL/6 mice. However, the gua mutants failed to protect mice against lethal challenge with WT Schu S4, despite demonstrating partial protection in rabbits in a previous study. These results contrast with the highly protective capacity of LVS gua mutants against a lethal LVS challenge in mice, and underscore differences between these strains and the animal models in which they are evaluated, and therefore have important implications for vaccine development.

Keywords: Francisella tularensis; vaccines; live attenuated; Schu S4; mutants; tularemia
was passaged in vitro until attenuated. LVS was tested in humans in the 1960s (Saslaw et al. 1961; Hornick and Eigelsbach 1966) and demonstrated partial protection against pulmonary challenge with a highly human virulent subsp. tulariensis strain, demonstrating proof of principle that a live-attenuated vaccine can protect against tularemia. We hypothesized that improved efficacy in humans against a highly virulent type A challenge would be achieved by developing a live-attenuated vaccine derived from a type A strain, Schu S4.

Using previously described techniques (Santiago et al. 2009), we generated 7 Schu S4 mutant strains containing unmarked, targeted deletions in the following Ft genes: FTT0507, FTT0584, FTT0742, FTT1019c (guaA), FTT1043, FTT1317c (guaB) and a double knockout of FTT1019c and FTT1317c (guaAguaB), as homologs of these genes have been previously demonstrated to be attenuating in Francisella spp. or other intracellular bacteria. In F. novicida, FTT0584 was required for suppression of the host ASC/caspase-1 pathway, which is important for innate immune defense (Henry and Monack 2007; Henry et al. 2007; Weiss et al. 2007; Monack 2008), and FTT0742 encodes a hypothetical lipoprotein that is predicted to form part of the F. novicida cell wall (Tempel et al. 2006); both were attenuating mutations in F. novicida. FTT0507 was identified in Ft subsp. tulariensis as a third member of the thioredoxin (TRX) family of proteins; TRX proteins play a major role in maintaining the redox environment of the cell (Inaba 2008, 2009; Inaba and Ito 2008; Ito and Inaba 2008; Qin et al. 2008, 2009; Heras et al. 2009). The presence of multiple TRX members in a single bacterium suggests that these proteins play a crucial role in the correct folding of many secreted or exposed virulence determinants (Inaba and Ito 2008; Ito and Inaba 2008; Heras et al. 2009). FTT1043 was identified as encoding a protein with similarity to macrophage infectivity potentiator (mip). Mip proteins have been well characterized in several human pathogens, including Legionella (Bangsorg, Cianciotto and Hindersson 1991; Cianciotto and Fields 1992; Wagner et al. 2007), Neisseria (Starnino et al. 2010; Hung et al. 2011), Coxiella (Mo, Cianciotto and Mallavia 1995; Seshu, McIvor and Mallavia 1997), Burkholderia (Norville et al. 2011) and Chlamydia (Lundemose et al. 1991; Rockey et al. 1996; Neff et al. 2007; Bas et al. 2008; Lu et al. 2013), and are required by Legionella pneumophila for invasion and proper intracellular establishment of infection in macrophages and protozoa (Cianciotto and Fields 1992). Finally, deletions in genes encoding metabolic enzymes including guaA and guaB have been demonstrated to attenuate Salmonella and Shigella spp. (Chatfield et al. 1994; Cersini, Salvia and Bernardini 1998; Kotloff et al. 2000, 2007). The guaA and guaB genes encode essential enzymes in guanine nucleotide biosynthesis and deletion of either gene is highly attenuating in LVS; additionally, LVS gua mutants were protective against subsequent lethal LVS challenge (Santiago et al. 2009).

The successful deletion of each gene(s) in Schu S4 was confirmed by PCR, and growth kinetics were evaluated in both broth and J774 macrophages, a preferential host cell type for Ft. Schu S4 mutants in FTT0507, FTT0584, FTT0742 and FTT1043 exhibited no defects and replicated in broth and macrophages with no significant differences in kinetics compared to WT. As expected, the Schu S4 ΔguaA single and double mutants were unable to grow in broth without exogenously added guanine, and growth of the mutants was restored by either addition of guanine to the media or trans-complementation of the gene (data not shown). Additionally, the Schu S4 ΔguaAΔguaB and ΔguaAΔguaAguaB mutants failed to replicate in macrophages, exhibiting decreased bacterial counts over the time course (P < 0.01 for all three mutants compared to WT at 24 h, Fig. 1). Each single gua mutant derivative was effectively complemented in trans, following a growth pattern that was comparable to that of the WT Schu S4 strain. The double ΔguaAΔguaB strain could not be complemented since the two genes could not be cloned and effectively expressed in a single plasmid. Results similar to those seen in J774.1 cells (Fig. 1) were also seen in primary murine peritoneal macrophages (data not shown).

The mutants were then assessed for attenuation in vivo using the C57BL/6 mouse model and compared to WT Schu S4 (intranasal LD<sub>50</sub> of Schu S4 is ~10 CFU; Chen et al. 2003). Our studies revealed that Schu S4ΔFTT0507 and Schu S4ΔFTT0584 retained WT levels of virulence; no animals survived intranasal challenge. Schu S4 ΔFTT0742 and Schu S4ΔFTT1043 were minimally attenuated, with 2/5 and 1/5 mice respectively surviving intranasal inoculation (Table 1). As these four strains did not show growth defects in vitro, these results were not unexpected. Interestingly, we determined that protein sequence variations may contribute to differing functions and levels of attenuation between mutants in Ft and F. novicida. Alignment of the F. novicida and Ft protein sequences for FTT0584 showed 88% identity over the first 1015 amino acids but the F. novicida homolog FTT0757 contains 506 C-terminal amino acids that are lacking in the Ft version. Similarly, FTT0742 is 79% identical to its F. novicida homolog FTT0714 but FTT0742 is truncated by 1190 residues. Truncation of these two F. novicida genes in Ft suggests the possibility that these may be pseudogenes in Ft, a common occurrence with Francisella, and would explain why these deletions show no phenotype in Ft. Likewise, FTT0507 and FTT1043, predicted to be important virulence factors in Ft, did not affect macrophage replication or significantly affect virulence in the mouse model. The lack of attenuation in the FTT1043 mutant is especially interesting given its homology to other mip genes in intracellular bacteria that have been demonstrated to be critical virulence factors (Lundemose et al. 1991; Cianciotto and Fields 1992; Mo, Cianciotto and Mallavia 1995; Rockey et al. 1996; Seshu, McIvor and Mallavia 1997; Neff et al. 2007; Wagner et al. 2007; Bas et al. 2008; Starnino et al. 2010; Hung et al. 2011; Norville et al. 2011; Qin et al. 2011; Qin, Scott and Mann 2013).

Only mutations in genes encoding enzymes in metabolic pathways including guaA and guaB significantly attenuated Schu
Table 1. In vivo attenuation and protective efficacy of Schu S4 mutants.

| Gene/strain | Function | Dose (i.n.) | Survival | Average time to death | Priming dose (i.n.) | Booster dose (i.n.) | Challenge dose (i.n.) | Survival | Average time to death |
|-------------|----------|-------------|----------|-----------------------|---------------------|---------------------|----------------------|----------|----------------------|
| WT Schu S4  |          | 2 × 10³     | 0/4      | 5                     |                     |                     |                      |          |                      |
| ΔFTT0507    | Thioredoxin-like oxoreductase | 2 × 10³ | 0/5 | 5.4                     |                     |                     |                      |          |                      |
| ΔFTT0584    | Innate immune response in Fn | 3 × 10³ | 0/5 | 6                     |                     |                     |                      |          |                      |
| ΔFTT0742    | Putative lipoprotein | 1 × 10³ | 2/5 | 14.2                   |                     |                     |                      |          |                      |
| ΔFTT1043    | Macrophage infectivity potentiator (mip)-like protein | 9 × 10² | 1/5 | 9.8                    |                     |                     |                      |          |                      |
| PBS         |          |             |          |                       |                     |                     |                      |          |                      |
| WT Schu S4  |          | 4 × 10²     | 0/4      | 5                     |                     |                     |                      |          |                      |
| ΔFTT1019c   | GMP synthetase (guaA) | 7 × 10⁵ | 3/3 | 28                     | 7 × 10⁶ | – | 100 | 0/3 | 4 |
|             |          | 7 × 10⁶ | 1/4 | 12.75                    |                     |                     |                      |          |                      |
|             |          | 7 × 10⁷ | 0/4 | 7.25                     |                     |                     |                      |          |                      |
| ΔFTT1317c   | IMP dehydrogenase (guaB) | 1 × 10⁴ | 4/4 | 28                     | 1 × 10⁵ | – | 95 | 0/4 | 6 |
|             |          | 1 × 10⁵ | 3/4 | 22.5                     | 6 × 10⁷ | 6 × 10⁷ | 100 | 0/4 | 4 |
|             |          | 1 × 10⁶ | 4/4 | 28                     |                     |                     |                      |          |                      |
|             |          | 1 × 10⁷ | 4/4 | 28                     |                     |                     |                      |          |                      |
|             |          | 6 × 10⁷ | 4/4 | 28                     |                     |                     |                      |          |                      |
| ΔFTT1019c   | guaA/guaB double mutant | 1 × 10⁸ | 4/4 | 28                     | 1 × 10⁴ | 1 × 10⁴ | 100 | 0/4 | 4 |
| ΔFTT1317c   |          |          |          |                       |                     |                     |                      |          |                      |

*Average time to death, in days, of mice that were euthanized; mice surviving for 28 days were not included in this calculation.

S4 in the mouse model (Table 1). All mice receiving 7 × 10⁵ CFU of Schu S4ΔguaA survived with no adverse clinical signs (Table 1, P < 0.05 compared to WT Schu S4). Schu S4ΔguaB was more highly attenuated and 100% of mice survived i.n. inoculation with 1 × 10⁵ CFU (P < 0.01 compared to WT). As expected, the double ΔguaAΔguaB strain was also highly attenuated and 100% of mice survived a dose of 1 × 10⁸ CFU (P < 0.01 compared to WT).

The high level of attenuation of the gua derivatives made them potential vaccine candidates. Their ability to induce protective responses was assessed in mice following either a single immunizing dose or a prime/boost regimen. Twenty-eight days following the last dose, mice were challenged via the i.n. route with a lethal dose of WT Schu S4. In contrast to the protective capacity, we documented with LVSΔguaA or LVSΔguaB mutants against a lethal LVS challenge in mice (Santiago et al. 2009), the Schu S4 Δgua derivatives did not confer protection against Schu S4 challenge (Table 1). None of the mice immunized with the highest safe dose of Schu S4ΔguaA, Schu S4ΔguaB (1 or 2 doses) or Schu S4ΔguaAΔguaB (2 doses) survived a challenge dose of 95–100 CFU Schu S4 (∼10 LD₅₀). In addition, time to death was not significantly increased following vaccination.

We also assessed cytokine expression in murine peritoneal macrophages infected with each of the gua mutants and found no significant differences in cytokine production between Schu S4 and either the Schu S4ΔguaA, ΔguaB or ΔguaAΔguaB strains (Fig. S1, Supporting Information). Interestingly, all three gua mutant strains elicited cytokine profiles similar to that of WT Schu S4 within 24 h of macrophage infection, with a rapid induction of TLR2 and TLR2-dependent transcription, including the cytokines TNF-α, IL-1β and neutrophil-attracting chemokine KC following infection of primary mouse macrophages, that decreased, but remained above uninfected levels at the 4 and 8-h time points. Expression of a second group of cytokines that are both TLR2- and IRF-3-dependent was induced after 4 h of infection when the TLR2 gene transcription wanes, and included IL-12 (p35 and p40), RANTES and iNOS. Transcription of these genes remained high until 8 h and decreased by 24 h post-infection. These observations were not entirely surprising, since analysis of Ft Schu S4 genome reveals several potential lipoproteins that may be involved in the activation of TLR2. Moreover, two lipoproteins (TUL4 and FTT1103) that can engage the TLR2 signaling pathway were not compromised during the gua mutagenesis process (Thakran et al. 2008). It is also possible that the
initial internalization of Ft, whether mutant or WT, triggers this cascade of responses which is not dependent on the ability of the bacteria to replicate within the macrophage. Alternatively, the mutant strains may be scavenging guanine from the host allowing for completion of the intracellular Ft life cycle, albeit at a slower pace. While critical for immune activation, this profile of cytokine induction is not sufficient to predict protective immunity since the mutant and WT strains induced similar levels of activation yet none were protective against a subsequent challenge.

Targeting critical biosynthetic pathway components has been a successful attenuating strategy for the Gram-negative enteric organisms Salmonella and Shigella (Hoiseth and Stocker 1981; Hone et al. 1991; Chatfield et al. 1994; Cersini, Salvia and Bernardini 1998; Kotloff et al. 2000, 2007) as well Ft LVS (Santiago et al. 2009). Furthermore, the Ft LVS ΔguaA and ΔguaB mutant strains elicited robust protection against a lethal LVS challenge in the mouse model (Santiago et al. 2009). It was therefore assumed that the Schu S4 ΔguaA and Schu S4 ΔguaB vaccine strains did not induce protection against a lethal Schu S4 challenge (Table 1), as these two gene sequences in LVS and Schu S4 are 99% identical. Pechous and colleagues reported similar findings where purMCD mutations in LVS were both highly attenuating and protective against virulent LVS challenge, but that the same mutations in Schu S4 provided limited protection against low dose Schu S4 challenge (Pechous et al. 2006, 2008). Other reports have documented differences in efficacy conferred by vaccines created in different background strains containing the same deletion when alternative animal models were employed (Cong et al. 2009; Signarovitz et al. 2012; Chu et al. 2014). Our data, although negative, underscore the importance of the background strain that is used in vaccine construction and emphasize the importance of demonstrating protection against the target type A strain. The Schu S4 ΔguaA ΔguaB strain, which was shown here to not be protective against challenge in mice, has recently been demonstrated to be partially protective against aerosol Schu S4 challenge in New Zealand white rabbits (Reed et al. 2014), providing evidence of the value of using more than one animal model to assess Ft vaccines. While the mouse model can provide critical information regarding the contributions of host genetics and immune responses to protective immunity, viable live-attenuated vaccine candidates may be eliminated because they are still too virulent for vaccination/challenge studies in the highly sensitive murine model. Alternative small animal models (including rabbits and rats), which are more resistant to Ft, may more accurately reflect the levels of reactivity and protection that would be seen in humans. As such, these findings highlight the importance of the differences between subspecies of Ft. tularensea and the use of appropriate models in tularemia vaccine studies.

ACKNOWLEDGEMENTS

This work was funded through the National Institute of Allergy and Infectious Disease, under grants RO1AI102966, U54AI57168, and U01AI077909.

SUPPLEMENTARY DATA

Supplementary data are available at FEMSPD online.

Conflict of interest. None declared.

REFERENCES

Bangsberg JM, Cianciotto NP, Hindersson P. Nucleotide sequence analysis of the Legionella micdadei mip gene, encoding a 30-kilodalton analog of the Legionella pneumophila Mip protein. Infect Immun 1991;59:3836–40.

Bas S, Neff L, Vuillet M, et al. The proinflammatory cytokine response to Chlamydia trachomatis elementary bodies in human macrophages is partly mediated by a lipoprotein, the macrophage infectivity potentiator, through TLR2/TLR1/TLR6 and CD14. J Immunol 2008;180:1158–68.

Cersini A, Salvia AM, Bernardini ML. Intracellular multiplication and virulence of Shigella flexneri auxotrophic mutants. Infect Immun 1998;66:549–57.

Chatfield S, Roberts M, Li J, et al. The use of live attenuated Salmonella for oral vaccination. Dev Biol Stand 1994;82:35–42.

Chen W, Shen H, Webb A, et al. Tularemia in BALB/c and C57BL/6 mice vaccinated with Francisella tularensis LVS and challenged intradermally, or by aerosol with virulent isolates of the pathogen: protection varies depending on pathogen virulence, route of exposure, and host genetic background. Vaccine 2003;21:3690–700.

Chu P, Cunningham AL, Yu JJ, et al. Live attenuated Francisella novicida vaccine protects against Francisella tularensis pulmonary challenge in rats and non-human primates. PLoS Pathog 2014;10:e1004439.

Cianciotto NP, Fields BS. Legionella pneumophila mip gene potentially intracellular infection of protozoa and human macrophages. P Natl Acad Sci USA 1992;89:5188–91.

Cong Y, Yu JF, Guentzel MN, et al. Vaccination with a defined Francisella tularensis subsp. novicida pathogenicity island mutant (Δgub) induces protective immunity against homotypic and heterotypic challenge. Vaccine 2009;27:5554–61.

Henry T, Brotcke A, Weiss DS, et al. Type I interferon signaling is required for activation of the inflammasome during Francisella infection. J Exp Med 2007;204:987–94.

Henry T, Monack DM. Activation of the inflammasome upon Francisella tularensis infection: interplay of innate immune pathways and virulence factors. Cell Microbiol 2007;9:2543–51.

Heras B, Shouldice SR, Totsika M, et al. DSB proteins and bacterial pathogenicity. Nat Rev Microbiol 2009;7:215–25.

Hoiseth SK, Stocker BA. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature 1981;291:238–9.

Hone DM, Harris AM, Chatfield S, et al. Construction of genetically defined double arg mutants of Salmonella typhi. Vaccine 1991;9:810–6.

Hornick RB, Eigelsbach HT. Aerogenic immunization of man with live Tularemia vaccine. Bacteriol Rev 1966;30:532–8.

Hung MC, Salim O, Williams JN, et al. The Neisseria meningitidis macrophage infectivity potentiator protein induces cross-strain serum bactericidal activity and is a potential serogroup B vaccine candidate. Infect Immun 2011;79:3784–91.

Inaba K. Protein disulfide bond generation in Escherichia coli. Disulfide bond disulfide generation machine. Biochim Biophys Acta 2008;1783:520–9.

Ito K, Inaba K. The disulfide bond formation (Db) system. Curr Opin Struct Biol 2008;18:450–8.

Kotloff KL, Noriega FR, Samandari T, et al. Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set,
and guaBA, is highly attenuated in humans. Infect Immun 2000;68:1034–9.

Kotloff KL, Simon JK, Pasetti MF, et al. Safety and immunogenicity of CVD 1208S, a live, oral ΔguaBA Δsen Δset Shigella flexneri 2a vaccine grown on animal-free media. Hum Vaccin 2007;3:268–75.

Lu C, Peng B, Li Z, et al. Induction of protective immunity against Chlamydia muridarum intravaginal infection with the chlamydial immunodominant antigen macrophage infectivity potentiator. Microbes Infect 2013;15:329–38.

Lundemose AG, Birkelund S, Fey SJ, et al. Chlamydia trachomatis contains a protein similar to the Legionella pneumophila mip gene product. Mol Microbiol 1991;5:109–15.

Mo YY, Cianciotto NP, Mallavia LP. Molecular cloning of a Coxiella burnetii gene encoding a macrophage infectivity potentiator (Mip) analogue. Microbiology 1995;141(Pt 11):2861–71.

Monack DM. The inflammasomes: a key player in the inflammation triggered in response to bacterial pathogens. J Pediatr Gastro Nutr 2008;46(Suppl 1):E14.

Neff L, Daher S, Muzzin P, et al. Molecular characterization and subcellular localization of macrophage infectivity potentiator, a Chlamydia trachomatis lipoprotein. J Bacteriol 2007;189:4739–48.

Norville IH, Harmer NJ, Harding SV, et al. A Burkholderia pseudomallei macrophage infectivity potentiator-like protein has rapamycin-inhibitable peptidylprolyl isomerase activity and pleiotropic effects on virulence. Infect Immun 2011;79:4299–307.

Pechous R, Celli J, Penoske R, et al. Construction and characterization of an attenuated purine auxotroph in a Francisella tularensis live vaccine strain. Infect Immun 2006;74:4452–61.

Pechous RD, McCarthy TR, Mohapatra NP, et al. A Francisella tularensis Schu S4 purine auxotroph is highly attenuated in mice but offers limited protection against homologous intranasal challenge. PLoS One 2008;3:e2487.

Qin A, Scott DW, Mann BJ. Francisella tularensis subsp. tularensis Schu S4 disulfide bond formation protein B, but not an RND-type efflux pump, is required for virulence. Infect Immun 2008;76:3086–92.

Qin A, Scott DW, Rabideau MM, et al. Requirement of the CXXC motif of novel Francisella infectivity potentiator protein B FipB, and FipA in virulence of F. tularensis subsp. tularensis. PLoS One 2011;6:e24611.

Qin A, Scott DW, Thompson JA, et al. Identification of an essential Francisella tularensis subsp. tularensis virulence factor. Infect Immun 2009;77:152–61.

Reed DS, Smith LP, Cole KS, et al. Live attenuated mutants of Francisella tularensis protect rabbits against aerosol challenge with a virulent type A strain. Infect Immun 2014;82:998–205.

Rockey DD, Chesebro BB, Heinzen RA, et al. A 28 kDa major immunogen of Chlamydia psittaci shares identity with Mip proteins of Legionella spp. and Chlamydia trachomatis-cloning and characterization of the C. psittaci mip-like gene. Microbiology 1996;142(Pt 4):945–53.

Santiago AE, Cole LE, Franco A, et al. Characterization of rationally attenuated Francisella tularensis vaccine strains that harbor deletions in the guaA and guaB genes. Vaccine 2009;27:2426–36.

Saslaw E, Eigelsbach HT, Prior JA, et al. Tularemia vaccine study. II. Respiratory challenge. Arch Intern Med 1961;107:702–14.

Seshu J, McIvor KL, Mallavia LP. Antibodies are generated during infection to Coxiella burnetii macrophage infectivity potentiator protein (Cb-Mip). Microbiol Immunol 1997;41:371–6.

Signarovitz AL, Ray HJ, Yu JJ, et al. Mucosal immunization with live attenuated Francisella novicida U112ΔiglB protects against pulmonary F. tularensis SCHU S4 in the Fischer 344 rat model. PLoS One 2012;7:e47639.

Starnino S, Leuzzi R, Chiisetti V, et al. Molecular analysis of two novel Neisseria gonorrhoeae virulent components: the macrophage infectivity potentiator and the outer membrane protein A. New Microbiol 2010;33:167–70.

Tempel R, Lai XH, Cosa L, et al. Attenuated Francisella novicida transposon mutants protect mice against wild-type challenge. Infect Immun 2006;74:5095–105.

Thakran S, Li H, Lavine CI, et al. Identification of Francisella tularensis lipoproteins that stimulate the toll-like receptor (TLR) 2/TLR1 heterodimer. J Biol Chem 2008;283:3751–60.

Wagner C, Khan AS, Kamphausen T, et al. Collagen binding protein Mip enables Legionella pneumophila to transmigrate through a barrier of NCI-H292 lung epithelial cells and extracellular matrix. Cell Microbiol 2007;9:450–62.

Weiss DS, Brotcke A, Henry T, et al. In vivo negative selection screen identifies genes required for Francisella virulence. P Natl Acad Sci USA 2007;104:6037–42.